Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efgartigimod alfa - argenx

Next Previous
X
Search
Drug Profile

Efgartigimod alfa - argenx

Alternative Names: ARGX-113; EFG PH20 SC; Efgartigimod - argenx; Efgartigimod alfa-fcab - argenx; efgartigimod PH20; efgartigimod PH20 SC; PH20 SC; VYVDURA; VYVGART; VYVGART HYTRULO

Latest Information Update: 21 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator arGEN-X
  • Developer argenx; Medison; ZAI Lab
  • Class Anti-inflammatories; Antiarrhythmics; Immunoglobulin Fc fragments; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Neonatal Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy; Myasthenia gravis; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Myasthenia gravis
  • Registered Idiopathic thrombocytopenic purpura
  • Phase III Bullous pemphigoid; Graves ophthalmopathy; Myositis; Pemphigus
  • Phase II Lupus nephritis; Membranous glomerulonephritis; Sjogren's syndrome
  • Clinical Phase Unknown Renal transplant rejection
  • Preclinical Immune-mediated necrotising myopathy
  • Discontinued Anti-neutrophil cytoplasmic antibody-associated vasculitis; Postural orthostatic tachycardia syndrome

Most Recent Events

  • 16 Aug 2024 Argenx plans a phase III trial for Myasthenia gravis in September 2024 (SC) (NCT06558279)
  • 14 Aug 2024 Argenx plans the phase III advance NEXT trial in Idiopathic thrombocytopenic purpura (IV) in October 2024 (NCT06544499)
  • 01 Aug 2024 University of South Florida plans a phase II trial for Stiff Person Syndrome in USA (SC) in August 2024 (NCT06528392)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top